Combinations are the Future in FLT3-Mutated AML

March 31st 2021

MET Exon 14 Skipping Mutations in Non–Small Cell Lung Cancer

March 29th 2021

Small-Cell Lung Cancer

March 25th 2021

Individualizing Treatment Approaches in MPN

February 26th 2021

2021: The Year of Advances in Unresectable HCC?

February 24th 2021

Key Advances in Endometrial Cancer

January 29th 2021

Treatment Approach in Advanced Melanoma

January 8th 2021

BCMA as a Target in Heavily Pre-Treated RRMM

December 18th 2020

Modern Perspectives in Advanced Melanoma

December 14th 2020

Emerging Strategies for Renal Cell Carcinoma

December 14th 2020

Treating Advanced RAI-Refractory DTC: A Two-Way Street: Medical Oncology and Endocrinology

December 14th 2020

Treatment Options in Metastatic Renal Cell Carcinoma

December 11th 2020

Contemporary Management of CLL

December 4th 2020

Treatment Options in Chronic Lymphocytic Leukemia: A Global Perspective

December 4th 2020

Treatment Options in Myelodysplastic Syndromes

November 18th 2020

Major Advances in RET Inhibition for NSCLC and MTC

November 16th 2020

Recent Developments in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

November 6th 2020

Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC

October 20th 2020

First Results of the Phase 3 CheckMate 9ER Trial

October 15th 2020

Key Updates in Melanoma from ESMO 2020

October 12th 2020